SE462075B - Oftalmologisk komposition foer behandling av glukom innehaallande kortverkande b-blockerande foereningar - Google Patents
Oftalmologisk komposition foer behandling av glukom innehaallande kortverkande b-blockerande foereningarInfo
- Publication number
- SE462075B SE462075B SE8300913A SE8300913A SE462075B SE 462075 B SE462075 B SE 462075B SE 8300913 A SE8300913 A SE 8300913A SE 8300913 A SE8300913 A SE 8300913A SE 462075 B SE462075 B SE 462075B
- Authority
- SE
- Sweden
- Prior art keywords
- carbon atoms
- composition according
- lower alkyl
- compound
- butyl
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims description 68
- 239000000203 mixture Substances 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 19
- -1 acetamido, amino Chemical group 0.000 claims abstract description 18
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims abstract description 14
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 9
- 125000005466 alkylenyl group Chemical group 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 5
- 230000000699 topical effect Effects 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000000644 isotonic solution Substances 0.000 claims description 2
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 abstract description 8
- 239000002876 beta blocker Substances 0.000 abstract description 7
- 229940097320 beta blocking agent Drugs 0.000 abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract description 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 2
- 150000002367 halogens Chemical class 0.000 abstract description 2
- 230000001384 anti-glaucoma Effects 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000001742 aqueous humor Anatomy 0.000 description 7
- 230000007071 enzymatic hydrolysis Effects 0.000 description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001839 systemic circulation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/276,658 US4454154A (en) | 1981-06-23 | 1981-06-23 | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8300913D0 SE8300913D0 (sv) | 1983-02-18 |
| SE8300913L SE8300913L (en) | 1983-02-18 |
| SE462075B true SE462075B (sv) | 1990-05-07 |
Family
ID=23057573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8300913A SE462075B (sv) | 1981-06-23 | 1983-02-18 | Oftalmologisk komposition foer behandling av glukom innehaallande kortverkande b-blockerande foereningar |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4454154A (es) |
| EP (1) | EP0082873B1 (es) |
| JP (1) | JPH0653663B2 (es) |
| AU (1) | AU565752B2 (es) |
| CA (1) | CA1188224A (es) |
| CH (1) | CH654205A5 (es) |
| ES (1) | ES513387A0 (es) |
| GB (1) | GB2111387B (es) |
| GR (1) | GR76847B (es) |
| IL (1) | IL66070A (es) |
| IT (1) | IT1156058B (es) |
| NL (1) | NL8220252A (es) |
| NZ (1) | NZ200972A (es) |
| PH (1) | PH18970A (es) |
| SE (1) | SE462075B (es) |
| WO (1) | WO1983000014A1 (es) |
| ZA (1) | ZA824340B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334601A (en) * | 1984-03-14 | 1994-08-02 | Bodor Nicholas S | Soft β-adrenergic blocking agents |
| US5202347A (en) * | 1984-03-14 | 1993-04-13 | Bodor Nicholas S | Soft β-adrenergic blocking agents |
| US5135926A (en) * | 1984-03-14 | 1992-08-04 | Bodor Nicholas S | Soft β-adrenergic blocking agents |
| US4609663A (en) * | 1984-09-11 | 1986-09-02 | Alcon Laboratories, Inc. | Aldose reductase inhibitors useful in glaucoma therapy |
| DE3871596T3 (de) * | 1987-04-03 | 2000-09-07 | Pharmacia & Upjohn Ab, Stockholm | Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes. |
| CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
| US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| US5536749A (en) * | 1994-10-13 | 1996-07-16 | Sl Pharmaceuticals, Inc. | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents |
| US6197817B1 (en) | 1999-01-22 | 2001-03-06 | Selectus Pharmaceuticals, Inc. | Phenylpropionic acids and esters: compounds and methods for inducing beta-blockade for the treatment of cardiac disorders |
| AU2005247480A1 (en) * | 2004-05-25 | 2005-12-08 | Qlt Inc. | Oculoselective drugs and prodrugs |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1593762A1 (de) * | 1967-02-06 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen substituierten 1-Phenoxy-2-hydroxy-3-alkylaminopropanen |
| US3868460A (en) * | 1967-02-06 | 1975-02-25 | Boehringer Sohn Ingelheim | Therapeutic compositions and method |
| US3740444A (en) * | 1968-01-25 | 1973-06-19 | Boehringer Sohn Ingelheim | Therapeutic compositions and method |
| GB1285038A (en) * | 1969-02-21 | 1972-08-09 | Ici Ltd | Alkanolamine derivatives |
| DE1922003C3 (de) * | 1969-04-30 | 1979-10-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | N-(3-Aryloxy-2-hydroxypropyl)-aminocarbonsäuren, deren Ester, Amide und Salze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung von Herzinsuffizienz |
| DE2048838A1 (de) * | 1970-10-05 | 1972-04-06 | C H Boehnnger Sohn, 6507 Ingel heim | Neue 1 Phenoxy 2 hydroxy 3 hydroxyal kylaminopropane und Verfahren zu ihrer Her stellung |
| FR2132570B1 (es) * | 1971-04-09 | 1974-08-02 | Lipha | |
| JPS4875539A (es) * | 1972-01-12 | 1973-10-11 | ||
| JPS49247A (es) * | 1972-04-17 | 1974-01-05 | ||
| US3839584A (en) * | 1972-08-31 | 1974-10-01 | Interx Research Corp | Pharmaceutical compositions containing a novel ester of ((methylamino)methyl)benzyl alcohol and methods of using same |
| AT330150B (de) * | 1973-02-28 | 1976-06-10 | Boehringer Sohn Ingelheim | Verfahren zur herstellung von neuen 1-phenoxy-2-hydroxy -3- propargylaminopropanen und von deren saureadditionssalzen |
| US3825583A (en) * | 1973-04-26 | 1974-07-23 | Interx Research Corp | Ester of 3-hydroxy-alpha-((methylamino)methyl)benzyl alcohol |
| US4195085A (en) * | 1975-09-26 | 1980-03-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate |
| US4146638A (en) * | 1976-02-17 | 1979-03-27 | Boehringer Ingelheim Gmbh | N-(3-phenoxy-2-hydroxy-propyl)-n-(2-phenyl-2-hydroxy-ethyl)-amines |
| US4191765A (en) * | 1976-05-25 | 1980-03-04 | Hoechst Aktiengesellschaft | 1-Aryloxy-2-hydroxy-3-aminopropanes |
| US4080471A (en) * | 1976-06-25 | 1978-03-21 | Aktiebolaget Hassle | Use of substituted isopropylaminopropanols for inducing inotropic effects of the human heart |
| DE2752659A1 (de) * | 1976-12-07 | 1978-06-08 | Sandoz Ag | Neue tetralinderivate, ihre herstellung und verwendung |
| US4127674A (en) * | 1977-03-21 | 1978-11-28 | Allergan Pharmaceuticals, Inc. | Method of treatment for glaucoma |
| EP0003664B1 (en) * | 1978-02-08 | 1982-02-17 | Imperial Chemical Industries Plc | Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| SE8004088L (sv) * | 1980-06-02 | 1981-12-03 | Haessle Ab | Nya substituerade 3-fenoxi-l-alkoxikarbonylalkylamino-propanol-2-er med beta-receptorblockerande egenskaper samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma och metod att ... |
| SE8004087L (sv) * | 1980-06-02 | 1981-12-03 | Haessle Ab | Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-er med betareceptorblockerande egenskaper, samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma, och metod att behandla akut ... |
| US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
-
1981
- 1981-06-23 US US06/276,658 patent/US4454154A/en not_active Expired - Fee Related
-
1982
- 1982-06-14 PH PH27416A patent/PH18970A/en unknown
- 1982-06-14 CA CA000405136A patent/CA1188224A/en not_active Expired
- 1982-06-15 NZ NZ200972A patent/NZ200972A/en unknown
- 1982-06-16 IL IL66070A patent/IL66070A/xx unknown
- 1982-06-18 GR GR68485A patent/GR76847B/el unknown
- 1982-06-18 ZA ZA824340A patent/ZA824340B/xx unknown
- 1982-06-22 IT IT67796/82A patent/IT1156058B/it active
- 1982-06-23 GB GB08303061A patent/GB2111387B/en not_active Expired
- 1982-06-23 WO PCT/US1982/000849 patent/WO1983000014A1/en active IP Right Grant
- 1982-06-23 JP JP57502293A patent/JPH0653663B2/ja not_active Expired - Lifetime
- 1982-06-23 NL NL8220252A patent/NL8220252A/nl unknown
- 1982-06-23 AU AU87374/82A patent/AU565752B2/en not_active Ceased
- 1982-06-23 EP EP82902333A patent/EP0082873B1/en not_active Expired
- 1982-06-23 CH CH1102/83A patent/CH654205A5/de not_active IP Right Cessation
- 1982-06-23 ES ES513387A patent/ES513387A0/es active Granted
-
1983
- 1983-02-18 SE SE8300913A patent/SE462075B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US4454154A (en) | 1984-06-12 |
| IL66070A (en) | 1987-03-31 |
| AU565752B2 (en) | 1987-09-24 |
| PH18970A (en) | 1985-11-26 |
| IT8267796A0 (it) | 1982-06-22 |
| GB2111387A (en) | 1983-07-06 |
| AU8737482A (en) | 1983-01-18 |
| CH654205A5 (de) | 1986-02-14 |
| IL66070A0 (en) | 1982-09-30 |
| ZA824340B (en) | 1983-04-27 |
| SE8300913D0 (sv) | 1983-02-18 |
| CA1188224A (en) | 1985-06-04 |
| SE8300913L (en) | 1983-02-18 |
| NL8220252A (nl) | 1983-05-02 |
| GB8303061D0 (en) | 1983-03-09 |
| WO1983000014A1 (en) | 1983-01-06 |
| EP0082873A1 (en) | 1983-07-06 |
| JPS58500996A (ja) | 1983-06-23 |
| NZ200972A (en) | 1986-10-08 |
| ES8401928A1 (es) | 1984-01-01 |
| EP0082873B1 (en) | 1988-12-07 |
| GR76847B (es) | 1984-09-04 |
| GB2111387B (en) | 1986-02-05 |
| JPH0653663B2 (ja) | 1994-07-20 |
| ES513387A0 (es) | 1984-01-01 |
| EP0082873A4 (en) | 1983-11-11 |
| IT1156058B (it) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5652236A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors | |
| US4599353A (en) | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma | |
| US5889020A (en) | Treatment of normotensive glaucoma with angiotensin II antagonists | |
| CA2013167A1 (en) | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension | |
| US7455855B2 (en) | Delivering substance and drug delivery system using the same | |
| SE462075B (sv) | Oftalmologisk komposition foer behandling av glukom innehaallande kortverkande b-blockerande foereningar | |
| US20240156830A1 (en) | Ophthalmic compositions of rifamycins and uses thereof | |
| SE464300B (sv) | Beta-adrenergiskt blockerande foerening samt kompositioner foer behandling av glaukom | |
| WO1996016647A2 (en) | Use of chloride channel blockers for reducing intraocular pressure | |
| US5583150A (en) | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases | |
| EP0664705B1 (en) | Compositions of ergoline derivatives for the treatment of glaucoma | |
| US5066664A (en) | 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents | |
| KR100192745B1 (ko) | 안질환 치료용 5-메틸-이속사졸-4-카르복실산아닐리드 및 2-하이드록시에틸리덴-시아노아세트산아닐리드 | |
| JP2002521333A (ja) | 高眼圧治療用眼薬組成物 | |
| JP2002501533A (ja) | 高眼圧症治療のための眼科用組成物 | |
| SE451069B (sv) | Anvendning av ett karbostyrilderivat for framstellning av ett lekemedel for behandling av glaukom | |
| EP0081581B1 (en) | Compositions for treating glaucoma | |
| US6232343B1 (en) | Ophthalmic preparations | |
| US4578403A (en) | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents | |
| NZ206385A (en) | Esters of 1,2,5-thiadiazole derivatives and pharmaceutical compositions | |
| AU583401B2 (en) | Increasing aqueous humor outflow | |
| MXPA06002484A (es) | Composiciones que comprenden derivados de benzo[g]quinolina y derivados de prostaglandina. | |
| EP0719553A1 (en) | Pharmaceutical composition for topical administration to the eye for treating allergic conjunctivitis | |
| JPS6232171B2 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8300913-4 Effective date: 19940110 Format of ref document f/p: F |